Gastric corpus atrophy following eradication of Helicobacter pylori.
BACKGROUND
Atrophic gastritis can develop in patients with Helicobacter pylori infection leading to a reduction in basal acid output. Whether the atrophy that develops is reversible is controversial.


OBJECTIVE
To investigate the effect of H. pylori eradication in infected subjects who had developed atrophy of the corpus mucosa.


METHODS
Ten H. pylori positive patients with corpus atrophy were identified at oesophagogastroduodenoscopy (OGD). They received eradication therapy with amoxicillin, clarithromycin and omeprazole. Repeat OGD with biopsy was performed at least 3 months later. Fasting plasma gastrin was measured at baseline and at re-endoscopy. H. pylori eradication was confirmed by 13C urea breath testing.


RESULTS
Median time to re-endoscopy was 5 months. There was improvement in corpus atrophy in 50% of patients after H. pylori eradication, and a significant reduction in plasma gastrin (P = 0.03). The index patients had a significant diminution of basal acid output compared to controls.


CONCLUSIONS
Corpus atrophy as defined by the Sydney System is reversible in some patients after H. pylori eradication. Improvement in atrophy is associated with a fall in fasting plasma gastrin levels. This may have implications in the prevention of gastric carcinoma.
Larkin
C J
CJ
Department of Medicine, Royal Victoria Hospital and Queen's University, Belfast, Northern Ireland.
Watson
P
P
Sloan
J M
JM
Ardill
J E
JE
Patterson
C C
CC
McCluggage
W G
WG
Buchanan
K D
KD
D000328:Adult; D000368:Aged; D001284:Atrophy; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology*; D005755:Gastrins / Q000097:blood; D005756:Gastritis / Q000473:pathology*; D016481:Helicobacter Infections / Q000473:pathology*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged
D005755:Gastrins